Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Survival analysis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,231 result(s) found for: Survival analysis. Displaying page 1 of 162.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-022902-41 Sponsor Protocol Number: BIG4-11/BO25126/TOC4939g Start Date*: 2011-09-26
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in pa...
    Medical condition: Patients with operable HER2-positive primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) ES (Ongoing) FR (Completed) IE (Completed) SE (Completed) DK (Completed) SI (Completed) NL (Completed) BE (Completed) SK (Completed) AT (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-001397-41 Sponsor Protocol Number: ASPIRIN_version1.0_Belgium Start Date*: 2017-07-31
    Sponsor Name:Antwerp University Hospital
    Full Title: A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients
    Medical condition: Patients with resected colon carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004340-11 Sponsor Protocol Number: 17403 Start Date*: 2018-06-13
    Sponsor Name:Bayer AG
    Full Title: A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or me...
    Medical condition: mRNA FGF receptor 1 and 3 positive locally advanced or metastatic urothelial carcinoma progressed after prior platinum-containing chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) NL (Prematurely Ended) FR (Completed) AT (Completed) CZ (Completed) ES (Completed) PT (Completed) FI (Completed) SK (Completed) HU (Completed) DK (Completed) BE (Completed) SE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004011-24 Sponsor Protocol Number: GO27826 Start Date*: 2012-09-14
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB (RO5185426) ADJUVANT THERAPY IN PATIENTS WITH SURGICALLY RESECTED, CUTANEOUS BRAF-MUTANT MELANOMA AT HIGH RISK FOR REC...
    Medical condition: Melanoma (patients with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma or patients with Stage IIIC cutaneous melanoma)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025669 Malignant melanoma stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) SE (Completed) CZ (Completed) DE (Completed) FR (Completed) BE (Completed) IT (Completed) ES (Completed) NL (Completed) EE (Completed) PT (Completed) IE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000128-22 Sponsor Protocol Number: FLIRT Start Date*: 2014-11-26
    Sponsor Name:LYSARC
    Full Title: A randomized phase III trial evaluating two strategies of rituximab administration for the treatment of first line/low tumor burden follicular lymphoma (Follicular Lymphoma IV/SC Rituximab Therapy)
    Medical condition: Stage II-IV follicular lymphoma grade 1-3a not previously treated
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-004438-24 Sponsor Protocol Number: M14-483 Start Date*: 2015-06-23
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: INTELLANCE 2: ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group.
    Medical condition: Glioblastoma Multiforme For Pediatric - High Grade Glioma and DIPG
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) HU (Completed) AT (Completed) FI (Completed) GB (Completed) IE (Completed) ES (Prematurely Ended) BE (Completed) CZ (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000042-34 Sponsor Protocol Number: C20-109-07 Start Date*: 2020-09-24
    Sponsor Name:
    Full Title: PROOF OF CONCEPT STUDY ON LTX-109 AS TREATMENT FOR HIDRADENITIS SUPPURATIVA
    Medical condition: Hidradenitis suppurativa, Hurley stage I-III
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2013-000266-11 Sponsor Protocol Number: 2012-772 Start Date*: 2014-05-27
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian cancer.
    Medical condition: Vulnerable elderly women with newly diagnosed stage III-IV ovarian cancer after an initial debulking surgery or with a planned interval debulking surgery.
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Completed) IE (Completed) DK (Prematurely Ended) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000899-15 Sponsor Protocol Number: EORTC-1531-ROG Start Date*: 2019-12-03
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: Radiotherapy and 6-month androgen deprivation therapy with or without apalutamide in Intermediate and Limited High Risk Localized Prostate Cancer: a phase III study
    Medical condition: Intermediate and Limited High Risk Localized Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015476-98 Sponsor Protocol Number: 1200.75 Start Date*: 2010-05-17
    Sponsor Name:Boehringer Ingelheim
    Full Title: LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one pri...
    Medical condition: patients with metastatic HER2 over-expressing breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) BE (Completed) DE (Completed) SK (Completed) PT (Completed) CZ (Completed) FR (Completed) AT (Completed) IT (Completed) ES (Completed) FI (Prematurely Ended) LT (Completed) LV (Completed) SI (Completed) GB (Completed) IE (Prematurely Ended) NO (Completed)
    Trial results: View results
    EudraCT Number: 2022-002736-31 Sponsor Protocol Number: ETOP22-22 Start Date*: 2023-05-04
    Sponsor Name:ETOP IBCSG Partners Foundation
    Full Title: A multicentre, single-arm phase II trial of adagrasib in patients with KRASG12C-mutant NSCLC, including the elderly (≥70 years) or patients with poor performance status
    Medical condition: Patients with KRASG12C-mutant stage IV NSCLC that had prior chemotherapy and/or immune-checkpoint inhibition or both.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001884-21 Sponsor Protocol Number: VTI-210 Start Date*: 2013-07-26
    Sponsor Name:VITAL THERAPIES INCORPORATED
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH SEVERE ACUTE ALCOHOLIC HEPATITIS (SAAH) AND LILLE SCORE FAILURE
    Medical condition: Severe Acute Alcoholic Hepatitis (sAAH)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10019805 - Hepatobiliary disorders 10019755 Hepatitis chronic active PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003691-12 Sponsor Protocol Number: TUD-CIRC01-071 Start Date*: 2019-12-04
    Sponsor Name:Technische Universität Dresden
    Full Title: Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) AIO-KRK-0217
    Medical condition: Colon cancer stage II
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009954 Colon cancer stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002447-16 Sponsor Protocol Number: 111482 Start Date*: 2008-11-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma
    Medical condition: Patients with histologically proven stage IIIB or IIIC cutaneous melanoma with macroscopic lymph node involvement suitable for surgical resection. Macroscopic lymph node involvement is defined as c...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) DE (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) FR (Completed) NL (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended) EE (Prematurely Ended) ES (Completed) AT (Prematurely Ended) GR (Prematurely Ended) BG (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003812-10 Sponsor Protocol Number: PHP-ICC-203 Start Date*: 2017-08-29
    Sponsor Name:Delcath Systems Inc.
    Full Title: A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Stand...
    Medical condition: Intrahepatic cholangiocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10073077 Intrahepatic cholangiocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005546-38 Sponsor Protocol Number: AEZS-108-050 Start Date*: 2013-10-14
    Sponsor Name:Aeterna Zentaris GmbH
    Full Title: Randomised controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer
    Medical condition: Endometrial cancer, advanced, recurrent or metastatic
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014741 Endometrial cancer stage IV PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014740 Endometrial cancer stage III PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) BE (Completed) GB (Completed) AT (Completed) DE (Completed) ES (Completed) IE (Completed) IT (Completed) BG (Completed) NL (Completed) PL (Completed) DK (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2015-001707-31 Sponsor Protocol Number: Protocolversion1.0 Start Date*: 2015-07-10
    Sponsor Name:Hull & East Yorkshire Hospitals NHS Trust
    Full Title: The SCaIPEL study: Survival and Quality of Life of Cancer Patients with Incidental Pulmonary Embolism Treated with LMWH
    Medical condition: Incidental Pulmonary Embolism in Cancer Patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001040-62 Sponsor Protocol Number: GBG78/BIG1-13 Start Date*: 2013-11-14
    Sponsor Name:GBG Forschungs GmbH
    Full Title: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor, in patients with hormone-receptor positive, HER2 normal primary breast cancer with high relapse r...
    Medical condition: About one-third of patient with hormone-receptor positive, HER2 negative breast cancer and residual disease after standard of care - including adequate surgery - have a substantial risk of relapse ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071113 Node-positive breast cancer LLT
    21.1 100000004865 10025025 Lumpectomy (breast cancer) LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073289 Premenopausal breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) ES (Completed) AT (Completed) IE (Completed) FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-002605-10 Sponsor Protocol Number: CJDQ443B12301 Start Date*: 2022-04-01
    Sponsor Name:Novartis Pharma AG
    Full Title: KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic K...
    Medical condition: Advanced non-small cell lung cancer harboring the KRAS G12C mutation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) HU (Trial now transitioned) ES (Ongoing) NO (Completed) GR (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) DK (Completed) SI (Trial now transitioned) EE (Completed) IT (Trial now transitioned) PL (Completed) HR (Completed) IS (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000551-41 Sponsor Protocol Number: IMPACT_Breast_6.3 Start Date*: 2014-03-18
    Sponsor Name:University Medical Center Groningen
    Full Title: Towards patient tailored cancer treatment supported by molecular imaging IMPACT: IMaging PAtients for Cancer drug selecTion – Metastatic Breast Cancer
    Medical condition: Metastatic Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 17:27:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA